• Company Type For Profit
  • Contact Email dlynch@apovax.com
  • Phone Number 5025691021

ApoVax, Inc., a biotechnology company, develops immunotherapies for regulating the immune system to fight against diseases. Its products include ApoVax104, a recombinant protein vaccine that combines with antigens, tumors, and infectious disease markers and stimulates an immune response to create a disease-specific vaccine or therapeutic; and

ProtEx, a technology that enables recombinant immunoregulatory proteins to be placed on the surface of cells, tissues, organs, and synthetic surfaces to modulate the immune system. The company’s products also include ApoVax104-HPV, a therapeutic vaccine for cervical cancer and human papillomavirus infection in women. In addition, its research programs c...

Lists Featuring This Company

Pharmaceutical Companies With Fewer Than 10 Employees
5,592 Number of Organizations • $19.1B Total Funding Amount • 3,794 Number of Investors
Southern US Pharmaceutical Companies
3,031 Number of Organizations • $29.3B Total Funding Amount • 1,344 Number of Investors
Pharmaceutical Companies With Less Than $50M in Revenue (Top 10K)
9,674 Number of Organizations • $186B Total Funding Amount • 11,865 Number of Investors
Southern US Biotechnology Companies
4,252 Number of Organizations • $62.6B Total Funding Amount • 4,075 Number of Investors

Frequently Asked Questions

Where is ApoVax's headquarters? ApoVax is located in Louisville, Kentucky, United States.How much funding has ApoVax raised to date? ApoVax has raised .When was the last funding round for ApoVax? ApoVax closed its last funding round on Nov 27, 2012 from a Debt Financing round.Who are ApoVax's competitors? Alternatives and possible competitors to ApoVax may include CEL-SCIImvax, and PaxVax.